BioMarin Announces Fourth Quarter and Full Year 2021 Financi

/PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months Ended...

Related Keywords

Australia , Japan , Ireland , United States , Canada , Brazil , America , Irish , Debra Charlesworth , Biomarin Aldurazyme , Traci Mccarty , Jean Jacques Bienaim , European Commission , Drug Administration , Biomarin Pharmaceutical Inc , Nasdaq , Replay International Number , International Number , Company Annual Report On Form , Exchange Commission , Development Expense , Development Portfolio , European Medicines Agency , Biomarin Genzyme , Committee For Medicinal Products Human Use , Three Months Ended December , Months Ended December , Product Revenues Marketed , Generally Accepted Accounting Principles , Sanofi Genzyme , Net Product Revenues , Marin Pharmaceutical , Chief Executive Officer , Middle East , Latin America , Regulatory Portfolio , Adverse Events , Marketing Authorization Applications , Medicinal Products , Human Use , Biologics License Application , Complete Response Letter , Investigational New Drug , Hereditary Angioedema , Orphan Disease Designation , Duchenne Muscular Dystrophy , Year Financial Guidance , Total Revenues , Financial Guidance , Canada Dial In Number , Dial In Number , International Dial In Number , Biomarin Pharmaceutical , Administrative Expense , Quarterly Report , Nonqualified Deferred Compensation , Consolidated Financial Statements , Annual Report , Twelve Months Ended December , Product Revenues , Net Product Revenues Marketed , Asset Amortization , Contingent Consideration , Intangible Asset , From Income Taxes , Guidance Year Ending December ,